13F Holdings
中文EN

ZNTL Zentalis Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1725160 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-33.8%
TTM net income YoY16.7%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-615.2%
Net margin-555.8%
FCF margin-498.8%
EBITDA margin-611.8%

Returns

ROE-49.2%
ROA-38.4%
ROIC (approx.)-49.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets22.7%
Debt / equity0.00x
Current ratio7.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$67.42M$0$0—
R&D expense$107.30M$167.77M$189.59M$172.73M$175.60M
SG&A expense$37.72M$87.11M$64.35M$54.55M$40.94M
Operating income-$152.81M-$191.19M-$299.51M-$227.29M-$216.54M
Pretax income-$136.62M-$165.69M-$292.91M-$237.58M-$166.39M
Income tax$442,000$177,000-$601,000-$469,000-$297,000
Net income-$137.06M-$165.84M-$292.19M-$236.81M-$158.72M
EBITDA-$152.07M-$189.91M-$298.12M-$225.86M-$216.00M
EPS (basic)-1.91-2.33-4.47-4.48-3.72
EPS (diluted)-1.91-2.33-4.47-4.48-3.72
Weighted avg. shares (diluted)71.87M71.08M65.41M52.86M42.69M
Balance sheet
Cash & equivalents$35.99M$36.53M$28.04M$45.70M$62.58M
Short-term investments$209.90M$318.01M$454.88M——
Receivables$0$5.00M$0—$4,000
Current assets$253.19M$386.07M$496.72M$451.93M$350.77M
PP&E, net$2.77M$4.70M$5.82M$7.71M$8.15M
Goodwill—$0$3.74M$3.74M$3.74M
Total assets$288.97M$430.34M$551.69M$539.31M$454.51M
Current liabilities$36.56M$52.73M$69.37M$56.65M$43.94M
Total liabilities$72.76M$93.15M$114.30M$105.29M$90.03M
Shareholders' equity$216.20M$337.19M$437.28M$433.80M$363.95M
Shares outstanding69.09M71.28M70.77M59.28M45.49M
Cash flow statement
Operating cash flow-$125.25M-$170.86M-$207.82M-$163.75M-$154.09M
Capital expenditure$0$221,000$583,000$2.55M$6.11M
Free cash flow-$125.25M-$171.08M-$208.41M-$166.30M-$160.20M
Investing cash flow$131.62M$176.56M-$44.46M-$114.18M-$18.11M
Financing cash flow-$4.28M$108,000$237.30M$261.04M$178.52M
Depreciation & amortization$739,000$1.29M$1.39M$1.43M$544,000
Stock-based compensation$20.72M$67.27M$54.82M$46.84M$35.74M
Share buybacks$9.98M$0$0——

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.